U.S. Markets open in 1 hr 52 mins

Quoin Pharmaceuticals, Ltd. (QNRX)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
2.7200+0.1400 (+5.43%)
At close: 04:00PM EDT
2.7500 +0.03 (+1.10%)
Pre-Market: 07:19AM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close2.5800
Bid2.6000 x 1100
Ask2.7900 x 900
Day's Range2.5300 - 2.7300
52 Week Range2.5200 - 243.0000
Avg. Volume2,597,912
Market Cap22.701M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
Earnings DateAug 18, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • GlobeNewswire

    Quoin Pharmaceuticals Establishes Patient Specific Website for Ongoing Netherton Syndrome Clinical Study

    Three clinical sites are now fully open; final three sites expected to open imminentlyASHBURN, Va., Sept. 13, 2022 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a specialty pharmaceutical company focused on rare and orphan diseases, has established a patient specific website:, to facilitate patient awareness and participation in its ongoing clinical study evaluating QRX003 for the treatment of Netherton

  • Zacks Small Cap Research

    QNRX: Enhanced Financial Flexibility to Move QRX003 & Other Assets Forward

    By M. Marin NASDAQ:QNRX READ THE FULL QNRX RESEARCH REPORT Recent milestones include enhancing financial flexibility to advance growth strategy … Quoin Pharmaceuticals (NASDAQ:QNRX) has strengthened its cash position and reached several milestones to continue moving its lead candidates and other assets forward. In 3Q22, Quoin closed an equity offering, raising net proceeds of about $15.0 million

  • GlobeNewswire

    Quoin Pharmaceuticals Provides Corporate Update and Announces Second Quarter 2022 Financial Results

    Initiates clinical trial evaluating lead product candidate, QRX003 for Netherton SyndromeExpands number of commercial partnerships to eight, covering 60 countriesSigns Research Agreement to develop a product for the treatment of scleroderma Closes $16.8 million public offering, with net proceeds of approximately $15.0 million ASHBURN, Va., Aug. 18, 2022 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a clinical stage, specialty pharmaceutical company foc